Form 4 for ELOX Eloxx Pharmaceuticals, Inc.
Accepted 2026-05-08 16:53:53 ET · period of report 2022-02-06 · accession 0001193125-26-214890 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-08 16:53 | 2025-08-14+ | ELOX | Aggarwal Sumit | Pres, CEO, Dir, 10% | M - OptEx | $0.0855 | +472.8K | 1.67M | +39% | +$40.4K |
| D | 2026-05-08 16:53 | 2025-09-19 | ELOX | Aggarwal Sumit | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +1.00M | 1.40M | +252% | $0 |
| DM | 2026-05-08 16:53 | 2022-02-06+ | ELOX | Aggarwal Sumit | Pres, CEO, Dir, 10% | A - Grant | $0.00 | +3.81M | 3.60M | New | $0 |
| DM | 2026-05-08 16:53 | 2024-10-16 | ELOX | Aggarwal Sumit | Pres, CEO, Dir, 10% | D - Sale to Iss | — | -171.9K | 0 | -100% | — |
| DM | 2026-05-08 16:53 | 2025-08-14+ | ELOX | Aggarwal Sumit | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -472.8K | 3.34M | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-14 | M | A | 196,880 | $0.0001 | 396,810 | D | — | — | |
| 2 | Common | Common Stock | 2025-09-19 | A | A | 1,000,000 | $0.00 | 1,396,810 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant. |
| 3 | Common | Common Stock | 2026-01-24 | M | A | 15,000 | — | 1,411,810 | D | — | — | (F2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. |
| 4 | Common | Common Stock | 2026-02-28 | M | A | 260,946 | $0.15 | 1,672,756 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-02-06 | A | A | 42,790 | $0.00 | 42,790 | D | $18.40 · — to 2032-02-06 | 42,790 Common Stock | (F4) On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. (F3) The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | D | D | 42,790 | — | 0 | D | $18.40 · — to 2032-02-06 | 42,790 Common Stock | (F4) On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. (F5) The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price. (F3) The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | A | A | 42,790 | — | 42,790 | D | $0.0001 · — to 2032-02-06 | 42,790 Common Stock | (F5) The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price. (F3) The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | D | D | 35,580 | — | 0 | D | $3.36 · — to 2031-04-01 | 35,580 Common Stock | (F4) On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. (F7) The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price. (F6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | A | A | 35,580 | — | 35,580 | D | $0.0001 · — to 2031-04-01 | 35,580 Common Stock | (F7) The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price. (F6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
| 10 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | D | D | 24,810 | — | 0 | D | $1.41 · — to 2031-04-01 | 24,810 Common Stock | (F4) On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split. (F8) The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price. (F6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
| 11 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | A | A | 24,810 | — | 24,810 | D | $0.0001 · — to 2031-04-01 | 24,810 Common Stock | (F8) The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price. (F6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
| 12 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | D | D | 68,700 | — | 0 | D | $4.27 · — to 2033-01-25 | 68,700 Common Stock | (F10) The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price. (F9) The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 13 | Derivative | Stock Option (Right to Buy) | 2024-10-16 | A | A | 68,700 | — | 68,700 | D | $0.0001 · — to 2033-01-25 | 68,700 Common Stock | (F10) The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price. (F9) The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 14 | Derivative | Stock Option (Right to Buy) | 2025-08-14 | M | D | 60,390 | $0.00 | 0 | D | $0.0001 · — to 2031-04-01 | 60,390 Common Stock | (F6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter. |
| 15 | Derivative | Stock Option (Right to Buy) | 2025-08-14 | M | D | 68,700 | $0.00 | 0 | D | $0.0001 · — to 2033-01-25 | 68,700 Common Stock | (F9) The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 16 | Derivative | Stock Option (Right to Buy) | 2025-08-14 | M | D | 25,000 | $0.00 | 0 | D | $0.0001 · — to 2033-08-23 | 25,000 Common Stock | (F11) The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise. |
| 17 | Derivative | Stock Option (Right to Buy) | 2025-08-14 | M | D | 42,790 | $0.00 | 0 | D | $0.0001 · — to 2032-02-06 | 42,790 Common Stock | (F3) The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise. |
| 18 | Derivative | Stock Option (Right to Buy) | 2025-09-19 | A | A | 3,597,090 | $0.00 | 3,597,090 | D | $0.15 · — to 2035-09-19 | 3,597,090 Common Stock | (F12) The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |
| 19 | Derivative | Restricted Stock Units | 2026-01-24 | M | D | 15,000 | $0.00 | 15,000 | D | — · — to — | 15,000 Common Stock | (F2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. (F13) The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter. (F13) The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter. |
| 20 | Derivative | Stock Option (Right to Buy) | 2026-02-28 | M | D | 260,946 | $0.00 | 3,336,144 | D | $0.15 · — to 2035-09-19 | 260,946 Common Stock | (F12) The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date. |